Group 1 - Shenjian Co., Ltd. reported a net profit of 33.65 million yuan for 2024, a year-on-year increase of 32.29%, with a proposed cash dividend of 0.5 yuan per 10 shares [1] - Jingce Electronics experienced a net loss of 97.60 million yuan in 2024, transitioning from profit to loss, despite a revenue increase of 5.59% to 2.565 billion yuan [1] - Jingwei Co., Ltd. reported a net profit of 35.54 million yuan for 2024, a decrease of 36.76%, with a proposed cash dividend of 1.00 yuan per 10 shares [1][2] Group 2 - Minsheng Health achieved a net profit of 91.83 million yuan in 2024, a year-on-year increase of 7.24%, with a proposed cash dividend of 1.00 yuan per 10 shares [2] - Zhongshe Co., Ltd. reported a net profit of 10.16 million yuan for 2024, a decline of 76.24%, with a proposed cash dividend of 0.2 yuan per 10 shares [3] - Keyuan Smart reported a net profit of 252 million yuan for 2024, a year-on-year increase of 56.64%, with a proposed cash dividend of 0.4 yuan per 10 shares [4] Group 3 - Beilu Pharmaceutical reported a net profit of 14.54 million yuan for Q1 2025, a year-on-year increase of 26.13%, with revenue of 283 million yuan [5] - Wangsu Technology achieved a net profit of 192 million yuan for Q1 2025, a year-on-year increase of 38.54%, with revenue of 1.235 billion yuan [6] - Keyuan Pharmaceutical reported a net profit of 23.08 million yuan for Q1 2025, a year-on-year increase of 7.25%, despite a revenue decline of 23.98% [7] Group 4 - Guangting Information reported a net profit of 24.03 million yuan for Q1 2025, turning from loss to profit, with revenue of 134 million yuan [9] - Zhaori Technology reported a net loss of 1.23 million yuan for Q1 2025, with revenue of 35.23 million yuan [11] - Huakai Yibai reported a net loss of 15.09 million yuan for Q1 2025, despite revenue growth of 35.08% to 2.292 billion yuan [13] Group 5 - Xinhongye reported a net profit of 34.43 million yuan for Q1 2025, a year-on-year increase of 20.43%, with revenue of 755 million yuan [15] - Huning Co., Ltd. reported a net profit of 3.61 million yuan for Q1 2025, a year-on-year decrease of 45.68%, with revenue of 64.51 million yuan [16] - Camel Co., Ltd. reported a net profit of 237 million yuan for Q1 2025, a year-on-year increase of 51.89%, with revenue of 4.136 billion yuan [17] Group 6 - Hengtong Co., Ltd. reported a net profit of 42.55 million yuan for Q1 2025, a year-on-year increase of 51.62%, with revenue of 313 million yuan [19] - Changqing Technology reported a net profit of 35.38 million yuan for Q1 2025, a year-on-year decrease of 23.80%, with revenue of 246 million yuan [21] - Libaba Co., Ltd. reported a net profit of 34.72 million yuan for Q1 2025, a year-on-year increase of 9.91%, with revenue of 419 million yuan [22] Group 7 - Shouxiangu reported a net profit of 58.37 million yuan for Q1 2025, a year-on-year decrease of 24.32%, with revenue of 171 million yuan [24] - Bojun Technology announced a stock issuance application accepted by the Shenzhen Stock Exchange [24] - Dayou Energy announced the full resumption of production at its Gengcun coal mine, with an annual production capacity of 3.6 million tons [25] Group 8 - Deyang Co., Ltd. successfully acquired land use rights for industrial land in Ningbo for 45.80 million yuan [27] - Tianyu Pharmaceutical's subsidiary received a drug registration certificate for an injectable product [29] - Xingwang Yuda signed a strategic cooperation agreement with the Jilin Province Bionic Robot Innovation Center [30] Group 9 - Lifang Pharmaceutical received approval for clinical trials of a new drug [32] - Zai Sheng Technology reported a net profit of 33.56 million yuan for Q1 2025, a year-on-year increase of 3.69%, with revenue of 324 million yuan [34] - Jinxin Technology reported a net profit of 319,920 yuan for Q1 2025, turning from loss to profit, with revenue of 563 million yuan [36] Group 10 - Huayin Electric reported a net profit of 75.67 million yuan for Q1 2025, a year-on-year increase of 894.61%, with revenue of 2.307 billion yuan [37] - Xinghua Co., Ltd. reported a net loss of 95.51 million yuan for Q1 2025, with revenue of 840 million yuan [38] - Heren Technology reported a net loss of 384,410 yuan for Q1 2025, with revenue of 78.40 million yuan [40] Group 11 - Fenda Technology reported a net profit of 40.45 million yuan for Q1 2025, a year-on-year increase of 84.07%, with revenue of 760 million yuan [41] - Tongda Co., Ltd. reported a net profit of 25.49 million yuan for 2024, a year-on-year decrease of 69.15%, with revenue of 6.201 billion yuan [43] - Zhonghe Holdings reported a net profit of 283 million yuan for 2024, a year-on-year decrease of 54.69%, with a proposed cash dividend of 0.3 yuan per 10 shares [44] Group 12 - Jiantou Energy reported a net profit of 531 million yuan for 2024, a year-on-year increase of 181.59%, with a proposed cash dividend of 1.3 yuan per 10 shares [44] - Guanghua Technology reported a net loss of 205 million yuan for 2024, with revenue of 2.589 billion yuan [45] - Huajin Technology reported a net profit of 29.26 billion yuan for 2024, a year-on-year increase of 8.1%, with a proposed cash dividend of 9 yuan per 10 shares [46] Group 13 - Yingke Medical reported a net profit of 1.465 billion yuan for 2024, a year-on-year increase of 282.63%, with a proposed cash dividend of 1.00 yuan per 10 shares [46] - Solar Energy reported a net profit of 1.225 billion yuan for 2024, a year-on-year decrease of 22.38%, with a proposed cash dividend of 0.56 yuan per 10 shares [46] - Dongfang Electric reported a net profit of 318 million yuan for 2024, a year-on-year decrease of 50.62%, with a proposed cash dividend of 0.32 yuan per 10 shares [47] Group 14 - Tianneng Heavy Industry reported a net loss of 262 million yuan for 2024, with revenue of 3.273 billion yuan [48] - Gangyan High-tech reported a net profit of 249 million yuan for 2024, a year-on-year decrease of 22.08%, with a proposed cash dividend of 1.00 yuan per 10 shares [48] - Shihua Machinery reported a net profit of 96.88 million yuan for 2024, a year-on-year increase of 5.35%, with revenue of 8.037 billion yuan [49] Group 15 - Gongtong Pharmaceutical reported a net loss of 27.59 million yuan for 2024, with revenue of 537 million yuan [51] - Zhongjing Electronics reported a net loss of 87.43 million yuan for 2024, with revenue of 2.932 billion yuan [53] - Yudai Development reported a net loss of 114 million yuan for 2024, with revenue of 388 million yuan [55] Group 16 - Zhenhua Technology reported a net profit of 970 million yuan for 2024, a year-on-year decrease of 63.83%, with a proposed cash dividend of 1.8 yuan per 10 shares [56] - Jierong Technology reported a net loss of 298 million yuan for 2024, with revenue of 1.357 billion yuan [58] - Changgao Electric New reported a net profit of 252 million yuan for 2024, a year-on-year increase of 45.66%, with a proposed cash dividend of 0.8 yuan per 10 shares [60] Group 17 - Shibao Detection announced a plan to acquire 81% of Zhonghuan Lianshu for 52.65 million yuan [61] - Jiangsu Boyun announced a plan to reduce its shareholding by up to 3% [62] - Jingfeng Mingyuan announced a plan to acquire 100% of Yichong Technology for 3.283 billion yuan [63]

Core Viewpoint - The company has announced its 2024 profit distribution plan, proposing a cash dividend of 0.3 RMB per 10 shares, which is subject to approval at the annual shareholders' meeting [17][18][19]. Financial Data Summary - The company reported a net profit of 206,514,122.67 RMB for the year 2024, with a total equity of 6,921,093,142.90 RMB as of December 31, 2024 [18][19]. - The total cash dividend amount is projected to be 51,845,540.88 RMB, which represents 36.64% of the company's net profit for the year [20][21]. Changes in Financial Indicators - The company’s cash dividend distribution plan is consistent with its past performance, as the cumulative cash dividends over the last three years have exceeded 30% of the average annual net profit [21]. - The company has maintained a reasonable cash dividend policy that aligns with its operational needs and shareholder returns [22]. Approval Process - The profit distribution plan was approved by the board of directors with unanimous support and is deemed to not adversely affect the company's operational cash flow [23][24]. - The supervisory board also approved the plan, confirming its compliance with legal regulations and the company's articles of association [24][25].

公司积极与通用技术集团旗下医疗机构开展协同，在全国21个省份开户102家，其中86家为等级医院； 开展供应链服务94家。"重药控股-中国医药商业联合体"在市场开发、市场准入、合同营销、产品资 源、渠道资源、品牌塑造等方面开展全方位、多层次合作。 同时，公司取得全国主流医药商业企业首张放射性药品经营资质，自建放射性药品仓库投入运营，引进 放射性药品氟[18F]、锝[99mTc]2个新品种，新增2家三甲医院放射性药品配送资格。 4月23日晚间，重药控股（000950）披露一季报，公司实现营业收入206.12亿元，同比增长5.03%；归母 净利润1.25亿元，同比增长21.63%；基本每股收益0.07元。报告期，公司器械销售、专业药房销售均实 现同比增长，其中器械销售32.8亿元，同比增长17%；专业药房销售9.4亿元，同比增长10%。 据了解，重药控股自加入通用技术集团以来，加速推进与通用技术集团的协同发展，实现全国网络布 局，成功开辟核药经营流通新领域，持续提升营销服务能力、供应链服务能力，完善产品矩阵，取得了 显著成效。 此外，全国性合同销售组织（CSO）合作项目——爱施健速碧林项目完成31个省份销售，日健中 ...

重庆化医控股集团财务有限公司 风险评估报告 大信专审字[2025]第8-00007号 大信会计师事务所（特殊普通合伙） WUYIGE CERTIFIED PUBLIC ACCOUNTANTS LLP. WUYIGE Certified Public Accountants.LLP 等略 1 号 15/F.Xuevuan International Tower No.1Zhichun Road,Haidian Dist. Beijing,China,100083 网 -- Internet: +86 (10) 82330558 +86 (10) 82327668 www.daxincna.com cn 重庆化医控股集团财务有限公司 风险评估报告 大信专审字[2025]第 8-00007 号 重药控股股份有限公司: 我们接受委托,审核了后附的重庆化医控股集团财务有限公司(以下简称"化医财务公司") 管理当局对 2024年12月 31 日与其经营资质、业务和风险状况相关的风险评估说明。建立健 全并合理设计风险管理体系并保持其有效性,保证风险管理政策与程序的真实性和完整性是 化医财务公司管理层的责任。我们的责任是对化 ...

重药控股股份有限公司 2024 年年度决算报告 重药控股股份有限公司（以下称"公司"）决算报表包括 2024 年 12 月 31 日 的资产负债表、2024 年度的利润表、2024 年度的现金流量表等。天职国际会计 师事务所（特殊普通合伙）已对其进行审计，并出具了标准无保留意见的审计报 告。 一、2024 年度财务状况综述 近年来，我国医疗体制改革持续深化的背景下，药品、器械的带量采购制度 常态化、行业规模不断增加，传统配送业务利润空间持续压降，对医药流通企业 的综合运营能力提出了更高的要求，进一步推动医药流通行业升级转型。 2024 年，公司实现营业收入 80,561,531,747.38 元，同比增长 2.76%。实现归 属于母公司股东的净利润 282,993,622.91 元，同比下降 54.69%。 公司采用追溯重塑法对 2023 年数据进行更正的原因： 经公司自查，2023 年公司部分收入未实质取得货物控制权，错误适用总额 法进行确认；部分收入在期后大额退货，且无有效证明材料、无合理退货理由； 部分收入无商业实质；部分收入实际确认时点与公司已披露会计政策不符。上述 问题导致公司 2023 年度财务报 ...

重药控股股份有限公司 2024 年度会计师事务所履职情况评估报告 项目合伙人、签字注册会计师、项目质量控制复核人基本信息如下： 重药控股股份有限公司（以下简称"公司"）聘请天职国际会计师事务所（特 殊普通合伙）（以下简称"天职国际"）作为公司 2024 年度财务报告与内部控制 审计机构。根据财政部、国务院国资委及中国证监会颁布的《国有企业、上市公 司选聘会计师事务所管理办法》，公司对天职国际 2024 年度年审过程中的履职 情况进行评估。经评估，公司认为天职国际资质等方面合规有效，履职保持独立 性，勤勉尽责，公允表达意见。具体情况如下： 一、资质条件 名称：天职国际会计师事务所（特殊普通合伙） 成立日期：1988 年 12 月 组织形式：特殊普通合伙企业 注册地址：北京市海淀区车公庄西路 19 号 68 号楼 A-1 和 A-5 区域 首席合伙人：邱靖之 截至 2023 年 12 月 31 日，天职国际合伙人 89 人，注册会计师 1165 人，签 署过证券服务业务审计报告的注册会计师 414 人。天职国际 2023 年度经审计的 收入总额 31.97 亿元，审计业务收入 26.41 亿元，证券业务收入 12 ...

重药控股股份有限公司 2025 年年度财务预算报告 一、编制说明 重药控股股份有限公司（以下简称"公司"）根据实际经营业绩、公司的战 略规划及现有市场环境和行业政策的影响，在充分考虑现实各项基础、经营能力、 未来的发展计划及下列各项基本假设的前提下，本着求实稳健的原则，编制本预 算报告。 二、2025 年预算编报范围 2024 年纳入集团合并范围的分公司、全资子公司和控股子公司；2025 年预 计新并购公司和新成立项目子公司也包含在内。 三、制定 2025 年预算的基本假设 （七）无其他不可抗力及不可预见因素对公司造成的重大不利影响。 四、2025 年主要预算指标 （一）经营指标 2025 年公司预计实现营业收入 850-900 亿元。 （二）投资预算 （一）公司所遵循的国家和地方的现行有关法律、法规和制度无重大变化； （二）公司主要经营所在地及业务涉及地区的社会经济环境无重大变化； （三）公司所处行业形势及市场行情无重大变化； （四）公司 2025 年度业务涉及的市场无重大变动； （五）公司主要业务的市场价格和供求关系不会有重大变化； （六）公司生产经营业务涉及的信贷利率、税收政策等将在正常范围内波动； 2 ...

2024 年度可持续发展报告 重药控股股份有限公 司 PEACE PHARMACY CHAIN 和平药房 公司电话：023-63910671 股票代码：000950 地址：重庆市渝北区金石大道 303 号 公司官网链接：http://www.cqphar.com | 报告前言 | /01 | | --- | --- | | 关于本报告 | /01 | | 董事长致辞 | /03 | | 关于我们 | /05 | | --- | --- | | 2024年度亮点绩效 | /13 | | 走进重药控股 | /05 | 指标索引 | /121 | | --- | --- | --- | --- | | 关于我们 | /05 | 读者反馈 | /123 | | ESG管理 | | | --- | --- | | ESG治理体系 | /17 | | 响应联合国可持续发展目标 | /17 | | 利益相关方沟通 | /19 | | 重要性议题识别 | /20 | | 合规治企，铸就清廉国企 | | | --- | --- | | 规范公司治理 | /25 | | 加强内部管理 | /27 | | 完善合规建设 | /31 ...

重药控股股份有限公司 2024年度监事会工作报告 | 序号 | 届次 | 会议内容 | | --- | --- | --- | | | | 3.《2023年度总法律顾问述职报告》 | | | | 4.《2023年度风险、合规、内控、法治"四位一体" | | | | 工作报告》 | | | | 5.《2023年年度报告全文及摘要》 | | | | 6.《2023年年度利润分配预案》 | | | | 7.《未来三年（2024年-2026年）股东分红回报规 | | | | 划》 | | | | 8.《2023年度财务决算报告》 | | | | 9.《2024年度财务预算报告》 | | | | 10.《2023年内部审计总结和2024年工作计划》 | | | | 11.《2023年度内部控制评价报告》 | | | | 12.《关于编制<重药控股2023年社会责任暨环境、 | | | | 社会、公司治理（ESG）报告>的议案》 | | | | 13.《重庆化医控股集团财务有限公司风险评估报 | | | | 告》 | | | | 14.《关于2023年日常关联交易执行情况及2024年 | | | | 日常关联交易预计的议 ...

重药控股股份有限公司 2024 年度内部控制评价报告 重药控股股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要 求（以下简称"企业内部控制规范体系"），结合重药控股股份有限公司（以下简 称"重药控股"或"公司"）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司 2024 年 12 月 31 日（内部控制评价报告基准日）的 内部控制有效性进行了评价。 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其 有效性，并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建 立和实施内部控制进行监督。经理层负责组织领导企业内部控制的日常运行。公 司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假 记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个 别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及 相关信息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存 在的固有局限性，故仅能为实现上述目标提供合理保证。此外，由于情况的变化 可 ...